Treatment of mild cognitive impairment (MCI)

Research output: Contribution to journalArticle

32 Citations (Scopus)

Abstract

Mild cognitive impairment (MCI), an intermediate stage between normalcy and dementia, is characterized by fewer symptoms and less functional decline than dementia with less established biological disease processes and is an attractive target for both symptomatic and disease progression therapies. It is always desirable to treat symptoms or slow disease at a stage where the individual is still largely functional. Therapeutic studies in MCI have either been symptomatic, usually of shorter duration or of longer multiyear terms to demonstrate whether disease progression is delayed. Symptomatic agents tested to date include donepezil, SGS-742, and Piracetam. No symptomatic drug study has demonstrated clinically convincing differences between placebo and the study medication. Disease progression trials in MCI investigations of 2 to 4 year durations have included donepezil, vitamin E, rivastigmine, galantamine and rofecoxib. None have demonstrated convincing effects in delaying longer term disease progression or conversion to dementia. Problems that may have undermined these trials; i) disease heterogeneity, ii) slow early progression of the disease, and iii) insensitive cognitive and functional instruments. Future MCI studies may benefit from the use of biomarkers such as apolipoprotein E (APOE4), cerebrospinal fluid amyloid-β 1-42 and Tau levels and PIB positivity on brain PET scans as well as more sensitive neuropsychological test measures may also more accurately reflect clinical changes related to drug effects.

Original languageEnglish
Pages (from-to)362-367
Number of pages6
JournalCurrent Alzheimer Research
Volume6
Issue number4
DOIs
StatePublished - Aug 2009

Fingerprint

Disease Progression
Dementia
Rivastigmine
Galantamine
Piracetam
Biological Phenomena
Therapeutics
Neuropsychological Tests
Apolipoproteins E
Vitamin E
Amyloid
Pharmaceutical Preparations
Positron-Emission Tomography
Cerebrospinal Fluid
Biomarkers
Placebos
Cognitive Dysfunction
Brain
donepezil

Keywords

  • APOE ε4 genotype
  • Disease progression
  • Donepezil
  • Galantamine
  • Mild cognitive impairment
  • Rivastigmine
  • Rofecoxib

ASJC Scopus subject areas

  • Neurology
  • Clinical Neurology

Cite this

Treatment of mild cognitive impairment (MCI). / Farlow, Martin.

In: Current Alzheimer Research, Vol. 6, No. 4, 08.2009, p. 362-367.

Research output: Contribution to journalArticle

@article{b908c8259260408f82512466f1eef7cd,
title = "Treatment of mild cognitive impairment (MCI)",
abstract = "Mild cognitive impairment (MCI), an intermediate stage between normalcy and dementia, is characterized by fewer symptoms and less functional decline than dementia with less established biological disease processes and is an attractive target for both symptomatic and disease progression therapies. It is always desirable to treat symptoms or slow disease at a stage where the individual is still largely functional. Therapeutic studies in MCI have either been symptomatic, usually of shorter duration or of longer multiyear terms to demonstrate whether disease progression is delayed. Symptomatic agents tested to date include donepezil, SGS-742, and Piracetam. No symptomatic drug study has demonstrated clinically convincing differences between placebo and the study medication. Disease progression trials in MCI investigations of 2 to 4 year durations have included donepezil, vitamin E, rivastigmine, galantamine and rofecoxib. None have demonstrated convincing effects in delaying longer term disease progression or conversion to dementia. Problems that may have undermined these trials; i) disease heterogeneity, ii) slow early progression of the disease, and iii) insensitive cognitive and functional instruments. Future MCI studies may benefit from the use of biomarkers such as apolipoprotein E (APOE4), cerebrospinal fluid amyloid-β 1-42 and Tau levels and PIB positivity on brain PET scans as well as more sensitive neuropsychological test measures may also more accurately reflect clinical changes related to drug effects.",
keywords = "APOE ε4 genotype, Disease progression, Donepezil, Galantamine, Mild cognitive impairment, Rivastigmine, Rofecoxib",
author = "Martin Farlow",
year = "2009",
month = "8",
doi = "10.2174/156720509788929282",
language = "English",
volume = "6",
pages = "362--367",
journal = "Current Alzheimer Research",
issn = "1567-2050",
publisher = "Bentham Science Publishers B.V.",
number = "4",

}

TY - JOUR

T1 - Treatment of mild cognitive impairment (MCI)

AU - Farlow, Martin

PY - 2009/8

Y1 - 2009/8

N2 - Mild cognitive impairment (MCI), an intermediate stage between normalcy and dementia, is characterized by fewer symptoms and less functional decline than dementia with less established biological disease processes and is an attractive target for both symptomatic and disease progression therapies. It is always desirable to treat symptoms or slow disease at a stage where the individual is still largely functional. Therapeutic studies in MCI have either been symptomatic, usually of shorter duration or of longer multiyear terms to demonstrate whether disease progression is delayed. Symptomatic agents tested to date include donepezil, SGS-742, and Piracetam. No symptomatic drug study has demonstrated clinically convincing differences between placebo and the study medication. Disease progression trials in MCI investigations of 2 to 4 year durations have included donepezil, vitamin E, rivastigmine, galantamine and rofecoxib. None have demonstrated convincing effects in delaying longer term disease progression or conversion to dementia. Problems that may have undermined these trials; i) disease heterogeneity, ii) slow early progression of the disease, and iii) insensitive cognitive and functional instruments. Future MCI studies may benefit from the use of biomarkers such as apolipoprotein E (APOE4), cerebrospinal fluid amyloid-β 1-42 and Tau levels and PIB positivity on brain PET scans as well as more sensitive neuropsychological test measures may also more accurately reflect clinical changes related to drug effects.

AB - Mild cognitive impairment (MCI), an intermediate stage between normalcy and dementia, is characterized by fewer symptoms and less functional decline than dementia with less established biological disease processes and is an attractive target for both symptomatic and disease progression therapies. It is always desirable to treat symptoms or slow disease at a stage where the individual is still largely functional. Therapeutic studies in MCI have either been symptomatic, usually of shorter duration or of longer multiyear terms to demonstrate whether disease progression is delayed. Symptomatic agents tested to date include donepezil, SGS-742, and Piracetam. No symptomatic drug study has demonstrated clinically convincing differences between placebo and the study medication. Disease progression trials in MCI investigations of 2 to 4 year durations have included donepezil, vitamin E, rivastigmine, galantamine and rofecoxib. None have demonstrated convincing effects in delaying longer term disease progression or conversion to dementia. Problems that may have undermined these trials; i) disease heterogeneity, ii) slow early progression of the disease, and iii) insensitive cognitive and functional instruments. Future MCI studies may benefit from the use of biomarkers such as apolipoprotein E (APOE4), cerebrospinal fluid amyloid-β 1-42 and Tau levels and PIB positivity on brain PET scans as well as more sensitive neuropsychological test measures may also more accurately reflect clinical changes related to drug effects.

KW - APOE ε4 genotype

KW - Disease progression

KW - Donepezil

KW - Galantamine

KW - Mild cognitive impairment

KW - Rivastigmine

KW - Rofecoxib

UR - http://www.scopus.com/inward/record.url?scp=69149106814&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=69149106814&partnerID=8YFLogxK

U2 - 10.2174/156720509788929282

DO - 10.2174/156720509788929282

M3 - Article

VL - 6

SP - 362

EP - 367

JO - Current Alzheimer Research

JF - Current Alzheimer Research

SN - 1567-2050

IS - 4

ER -